Skip to main content

Table 1 Study procedures and flow-chart

From: Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

 

Screening 14 days

d1, d30, d60, d90, d120

After the 4thmonth, every 3 months until tolerance or progession

Physical exam

X

X

X

Safety

X

X

X

Availbility of tumour sample

X

  

Thoracic and abdominopelvic CT-Scann

X

X

X

Echocardio or MUGA

X

 

X

Hematology INR TCA

X

X

X

Biochemistry (1)

X

X

X

Urine Dipstick

X

X

X

Serum sample for TR programm

 

X

 
  1. (1) Serum creatinine, Glomerular filtration rate (Cockroff and Gault), AST, ALT, Bilirubin, Alkaline phosphatases, Amylase and lipase, CPK.